US Patent

US11040018 — Formulation for inhibiting formation of 5-HT2B agonists and methods of using same

Method of Use · Assigned to Zogenix International Ltd · Expires 2037-08-02 · 11y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a formulation of combining a first drug with a CYP inhibitor to modulate the formation of a metabolite with adverse side effects.

USPTO Abstract

Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT 2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2861 — fenfluramine-hydrochloride

Patent Metadata

Patent number
US11040018
Jurisdiction
US
Classification
Method of Use
Expires
2037-08-02
Drug substance claim
No
Drug product claim
No
Assignee
Zogenix International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.